A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Status:
Completed
Trial end date:
2016-12-27
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50
mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested
at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI
therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-naïve adult
subjects.